Skip to main content

Advertisement

Table 6 Pattern of change in PROs among dual and triple users prior, during and at the end of treatment

From: Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt

Variables/Time Triple therapy N = 26 Dual therapy N = 10
Mean + SD Chi-Square P-value Mean + SD Chi-Square P-value
HRQoL  
 T0 29.81 ± 15.87 10.26 .006 34.20 ± 13.98 .47 .79
 T1 43.35 ± 21.15 30.00 ± 18.63
 T2 37.54 ± 20.47 26.60 ± 17.02
Symptom experience  
 Symptom severity  
  T0 22.69 ± 10.29 8.00 .01 24.50 ± 10.46 .68 .71
  T1 29.77 ± 12.31 21.10 ± 13.54
  T2 26.58 ± 12.29 18.20 ± 12.51
 Symptom hindrance  
  T0 7.12 ± 6.67 13.01 .001 9.70 ± 5.54 .15 .92
  T1 13.58 ± 9.66 8.90 ± 6.23
  T2 10.96 ± 8.72 8.40 ± 5.10
Mental Health  
 Depression  
  T0 8.58 ± 6.65 11.40 .003 9.80 ± 8.99 5.70 .05
  T1 10.62 ± 6.93 11.20 ± 8.18
  T2 10.04 ± 6.40 6.20 ± 6.49
 Anxiety  
  T0 7.69 ± 6.04 4.95 .08 6.40 ± 5.29 2.10 .34
  T1 9.62 ± 5.97 7.00 ± 5.46
  T2 7.77 ± 6.62 4.50 ± 3.54
 Stress  
  T0 11.54 ± 7.27 4.93 .08 9.40 ± 7.72 .70 .70
  T1 12.92 ± 6.63 9.80 ± 7.19
  T2 11.04 ± 6.99 6.40 ± 5.17
 MSPSS  
  T0 2.45 ± .40 6.65 .03 2.31 ± .64 6.58 .03
  T1 2.54 ± .35 2.43 ± .44
  T2 2.42 ± .40 2.41 ± .41
  1. HRQoL health-related quality of life, T0 time 0, T1time 1, T2time 2, MSPSS Multidimensional Scale of Perceived Social Support
  2. P value significant at two tailed